Quirónsalud and Roche Farma Sign an Agreement to Promote Healthcare Innovation and Research

Quirónsalud and Roche Farma España have signed a framework agreement for collaboration to promote healthcare innovation and clinical research for the benefit of patients. This agreement was signed by Patrick Wallach, general manager of Roche Farma España , and Dr. Cristina Caramés , healthcare and research director of Quirónsalud, at an event attended by representatives of both organizations.

Specifically, the agreement aims to promote clinical research of excellence in Quirónsalud centres and favour early access to innovation for patients. This effort will focus on therapeutic areas with unmet needs, such as oncology, neurosciences and ophthalmology .

Quirónsalud and Roche Farma will collaborate to advance in oncology, neurosciences and ophthalmology, among other areas

The agreement also includes the development of precision medicine projects and the training of professionals through workshops and conferences, initiatives designed to improve the quality of care and the health of patients.

“This strategic agreement will allow us to join forces with Quirónsalud to generate significant added value in the field of healthcare innovation and biomedical research, with the aim of offering better health outcomes for patients,” said Patrick Wallach, who thanked the hospital group for its willingness to collaborate.

For her part, Dr. Cristina Caramés stressed that “agreements such as this will allow us to continue promoting innovation and the intense research activity of Quirónsalud, with more than 1,300 clinical trials underway over the last year, with the aim of offering our patients innovative solutions for their health care.” After signing the agreement, representatives of both companies held a working meeting to address issues of common interest.

__

(Featured image by National Cancer Institute via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in iSanidad. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us